Following a limited submission
AWMSG advice |
|||
| Status: Recommended | |||
Leuprorelin acetate (Prostap® SR DCS/Prostap® 3 DCS) is recommended as an option for use within NHS Wales as neoadjuvant treatment prior to radiotherapy in patients with high risk localised or locally advanced prostate cancer. |
|||
|
|||
Medicine details |
|||
| Medicine name | leuprorelin acetate (Prostap® SR DCS/Prostap® 3 DCS) | ||
| Formulation | 3.75 mg powder and solvent for prolonged-release suspension for injection, 11.25 mg powder and solvent for prolonged-release suspension for injection | ||
| Reference number | 2419 | ||
| Indication | Neoadjuvant treatment prior to radiotherapy in patients with high risk localised or locally advanced prostate cancer |
||
| Company | Takeda UK Ltd | ||
| BNF chapter | Malignant disease & immunosuppression | ||
| Submission type | Limited | ||
| Status | Recommended | ||
| Advice number | 3814 | ||
| NMG meeting date | 15/10/2014 | ||
| AWMSG meeting date | 12/11/2014 | ||
| Ratification by Welsh Government | 09/01/2015 | ||
| Date of issue | 13/01/2015 | ||
| Date of last review | 20/12/2017 | ||